Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design

被引：197

作者：

Dymock, BW

Barril, X

Brough, PA

Cansfield, JE

Massey, A

McDonald, E

Hubbard, RE

Surgenor, A

Roughley, SD

Webb, P

Workman, P

Wright, L

Drysdale, MJ

机构：

[1] Vernalis Ltd, Cambridge CB1 6GB, England

[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 13期

关键词：

D O I：

10.1021/jm050355z

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The crystal structure of a previously reported screening hit 1 (CCT018159) bound to the N terminal domain of molecular chaperone Hsp90 has been used to design 5-amide analogues. These exhibit enhanced potency against the target in binding and functional assays with accompanying appropriate cellular pharmaeodynamic changes. Compound 11 (VER-49009) compares favorably with the clinically evaluated 17-AAG.

引用

页码：4212 / 4215

页数：4

共 27 条

[1] AHERNE GW, 2003, P AM ASSOC CANC RES, V44, P915
[2] AHERNE GW, 2003, METHODS MOL MED NOVE, V85, P149
[3] BANERJI U, 2001, P AN M AM SOC CLIN, V20, pA82
[4] CHEUNG KM, IN PRESS BIOORG MED
[5] Chiosis G, 2003, MOL CANCER THER, V2, P123
[6] A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
Chiosis, G
Timaul, MN
Lucas, B
Munster, PN
Zheng, FF
Sepp-Lorenzino, L
Rosen, N
[J]. CHEMISTRY & BIOLOGY, 2001, 8 (03): : 289 - 299
[7] Adenine derived inhibitors of the molecular chaperone HSP90 - SAR explained through multiple X-ray structures
Dymock, B
Barril, X
Beswick, M
Collier, A
Davies, N
Drysdale, M
Fink, A
Fromont, C
Hubbard, RE
Massey, A
Surgenor, A
Wright, L
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (02) : 325 - 328
[8] Inhibitors of HSP90 and other chaperones for the treatment of cancer
Dymock, BW
Drysdale, MJ
McDonald, E
Workman, P
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (06) : 837 - 847
[9] Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats
Egorin, MJ
Lagattuta, TF
Hamburger, DR
Covey, JM
White, KD
Musser, SM
Eiseman, JL
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (01) : 7 - 19
[10] Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1
Egorin, MJ
Zuhowski, EG
Rosen, DM
Sentz, DL
Covey, JM
Eiseman, JL
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (04) : 291 - 302

← 1 2 3 →